Cure My Disease

Don't miss your cure!

 Log in / Sign up

Your DNA may determine if the Dentist's needle works

NCT ID NCT07697300

Knowledge-focused Sponsor: Marmara University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 15, 2026 · Updated 2 times

Summary

This study looks at whether certain genetic variations (in COMT, MAOA, and SLC6A4) influence how well a standard dental numbing injection works for people with a painful tooth condition called irreversible pulpitis. Participants received a numbing shot and had their pain levels measured during root canal treatment. The goal is to see if genetics can predict who might need a different approach to achieve effective pain relief.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
4% articaine with epinephrine
What this could lead to
If certain genes are linked to anesthesia failure, dentists could one day tailor numbing methods to a patient's genetic profile, improving pain control.
What could go wrong
This is a small, early-stage observational study. The results may not apply to all people or other types of anesthesia, and genetic testing in dentistry is not yet routine.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

95 people

The number who actually took part.

Started

Nov 2025

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

15 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Age between 15 and 60 years. American Society of Anesthesiologists (ASA) Physical Status I. Clinical diagnosis of symptomatic irreversible pulpitis in a mandibular molar requiring primary root canal treatment. Positive response to both the cold test and electric pulp test before treatment. Presence of pulpal bleeding upon access cavity preparation, confirming pulp vitality. Periodontal probing depth ≤3 mm. Sufficient coronal tooth structure to allow rubber dam isolation. No use of nonsteroidal anti-inflammatory drugs (NSAIDs) within 12 hours before enrollment. No known allergy or hypersensitivity to articaine or epinephrine. No history of systemic or genetic disease. Ability and willingness to provide written informed consent. Exclusion Criteria: Previous endodontic treatment of the study tooth. Extensive coronal destruction preventing rubber dam isolation. Internal or external root resorption. Periodontal probing depth \>3 mm. Pregnancy or breastfeeding. Known allergy or hypersensitivity to articaine or epinephrine. Use of nonsteroidal anti-inflammatory drugs (NSAIDs) within 12 hours before enrollment. Presence of any systemic or genetic disease. Inability or unwillingness to provide written informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Symptomatic irreversible pulpitis (SIP) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulpitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Symptomatic irreversible pulpitis (SIP)

Contacts and locations

Locations

  • Faculty of Dentistry, Marmara University

    Istanbul, Istanbul, 34854, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.